Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
AIMS: As promising compounds to lower Lipoprotein(a) (Lp(a)) are emerging, the need for a precise characterization and comparability of the Lp(a)-associated cardiovascular risk is increasing. Therefore, we aimed to evaluate the distribution of Lp(a) concentrations across the European population, to characterize the association with cardiovascular outcomes and to provide high comparability of the Lp(a)-associated cardiovascular risk by use of centrally determined Lp(a) concentrations. METHODS AND RESULTS: Based on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE)-project, we analysed data of 56 804 participants from 7 prospective population-based cohorts across Europe with a maximum follow-up of 24 years. All Lp(a) measurements were performed in the central BiomarCaRE laboratory (Biokit Quantia Lp(a)-Test; Abbott Diagnostics). The three endpoints considered were incident major coronary events (MCE), incident cardiovascular disease (CVD) events, and total mortality. We found lower Lp(a) levels in Northern European cohorts (median 4.9 mg/dL) compared to central (median 7.9 mg/dL) and Southern European cohorts (10.9 mg/dL) (Jonckheere-Terpstra test P < 0.001). Kaplan-Meier curves showed the highest event rate of MCE and CVD events for Lp(a) levels ≥90th percentile (log-rank test: P < 0.001 for MCE and CVD). Cox regression models adjusted for age, sex, and cardiovascular risk factors revealed a significant association of Lp(a) levels with MCE and CVD with a hazard ratio (HR) of 1.30 for MCE [95% confidence interval (CI) 1.15‒1.46] and of 1.25 for CVD (95% CI 1.12‒1.39) for Lp(a) levels in the 67‒89th percentile and a HR of 1.49 for MCE (95% CI 1.29‒1.73) and of 1.44 for CVD (95% CI 1.25‒1.65) for Lp(a) levels ≥ 90th percentile vs. Lp(a) levels in the lowest third (P < 0.001 for all). There was no significant association between Lp(a) levels and total mortality. Subgroup analysis for a continuous version of cube root transformed Lp(a) identified the highest Lp(a)-associated risk in individuals with diabetes [HR for MCE 1.31 (95% CI 1.15‒1.50)] and for CVD 1.22 (95% CI 1.08‒1.38) compared to those without diabetes [HR for MCE 1.15 (95% CI 1.08‒1.21; HR for CVD 1.13 (1.07-1.19)] while no difference of the Lp(a)- associated risk were seen for other cardiovascular high risk states. The addition of Lp(a) levels to a prognostic model for MCE and CVD revealed only a marginal but significant C-index discrimination measure increase (0.001 for MCE and CVD; P < 0.05) and net reclassification improvement (0.010 for MCE and 0.011 for CVD). CONCLUSION: In this large dataset on harmonized Lp(a) determination, we observed regional differences within the European population. Elevated Lp(a) was robustly associated with an increased risk for MCE and CVD in particular among individuals with diabetes. These results may lead to better identification of target populations who might benefit from future Lp(a)-lowering therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Self-citation2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citationAdjusting for multiple testing—when and how?
Bender, R., & Lange, S. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00314-0 · Cited by 3,004 · cited 1×
“No adjustment for multiple testing was performed due to the exploratory nature of the analyses.(19) The C-index(20) and the net reclassification improvement (NRI)(21,22) were used to quantify the added predictive value of Lp(a) beyond that from a model including classical risk factors.”
MethodExtensions of net reclassification improvement calculations to measure usefulness of new biomarkers
Pencina, M. J., D'Agostino, R. B., & Steyerberg, E. W. (2011) · Statistics in Medicine · doi:10.1002/sim.4085 · Cited by 2,453 · cited 1×
“A version of NRI appropriate for survival analyses was computed using the Kaplan–Meier method.(22) The overall NRI does not represent a proportion and is therefore reported as a decimal number between -2 and 2 rather than a percentage, as recommended by Leening and colleagues.”
MethodLipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807 · cited 1×
“<50 mg/dL which is the suggested cut-off according to the ESC guidelines.(7,17) These predefined categories were applied in the overall BiomarCaRE cohort.”
Method(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Self-citationA DISTRIBUTION-FREE k-SAMPLE TEST AGAINST ORDERED ALTERNATIVES
JONCKHEERE, A. R. (1954) · Biometrika · doi:10.1093/biomet/41.1-2.133 · Cited by 1,500
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357 · cited 1×
“6 for >_95th percentile.(5) In addition to the percentilebased analyses which are performed by the vast majority of Lp(a) studies we applied the clinically important threshold of 50 mg/dL and found a strong association for MCE and CVD events for Lp(a) levels >_50 mg/dL compared to Lp(a) levels <50 mg/dL.”
Background
Cited by
Patel, A. P., Wang, M., Pirruccello, J. P., Ellinor, P. T., Ng, K., Kathiresan, S., & Khera, A. V. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315291 · Cited by 567
Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review
Duarte Lau, F., & Giugliano, R. P. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0987 · Cited by 363
High lipoprotein(a) and high risk of mortality
Langsted, A., Kamstrup, P. R., & Nordestgaard, B. G. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy902 · Cited by 288
A new perspective on lipid research in age-related macular degeneration
van Leeuwen, E. M., Emri, E., Merle, B. M. J., Colijn, J. M., Kersten, E., Cougnard-Gregoire, A., Dammeier, S., Meester-Smoor, M., Pool, F. M., de Jong, E. K., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.04.006 · Cited by 247
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Schwartz, G. G., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., Jukema, J. W., Landmesser, U., López-Jaramillo, P., Manvelian, G., Pordy, R., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.102 · Cited by 150
Self-citation
Metadata
- Authors
- Waldeyer, C., Makarova, N., Zeller, T., Schnabel, R. B., Brunner, F. J., Jørgensen, T., Linneberg, A., Niiranen, T., Salomaa, V., Jousilahti, P., Yarnell, J., Ferrario, M. M., Veronesi, G., Brambilla, P., Signorini, S. G., Iacoviello, L., Costanzo, S., Giampaoli, S., Palmieri, L., Meisinger, C., Thorand, B., Kee, F., Koenig, W., Ojeda, F., Kontto, J., Landmesser, U., Kuulasmaa, K., & Blankenberg, S.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-04-24
- Volume
- 38
- Issue
- 32
- Pages
- 2490-2498
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2608584995
- Cited by
- 242
- References
- 38
- FWCI
- 23.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. https://app.cochat.ai/papers/10.1093/eurheartj/ehx166
- The paper
- Waldeyer, C., Makarova, N., Zeller, T., Schnabel, R. B., Brunner, F. J., Jørgensen, T., Linneberg, A., Niiranen, T., Salomaa, V., Jousilahti, P., Yarnell, J., Ferrario, M. M., Veronesi, G., Brambilla, P., Signorini, S. G., Iacoviello, L., Costanzo, S., Giampaoli, S., Palmieri, L., . . . Blankenberg, S. (2017). Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. European Heart Journal. https://doi.org/10.1093/eurheartj/ehx166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.